About Arcutis
Arcutis is a company based in Westlake Village (United States) founded in 2016 by Bhaskar Chaudhuri.. Arcutis has raised $94.5 million across 1 funding round from investors including Goldman Sachs, BlackRock and Vivo Capital. The company has 342 employees as of December 31, 2024. Arcutis has completed 1 acquisition, including Ducentis BioTheapeutics. Arcutis offers products and services including ZORYVE cream, ZORYVE foam, ARQ-252, ARQ-255, and ARQ-234. Arcutis operates in a competitive market with competitors including LEO Pharma, Incyte, Formation Bio, DermBiont and Evommune, among others.
- Headquarter Westlake Village, United States
- Employees 342 as on 31 Dec, 2024
- Founders Bhaskar Chaudhuri
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Arcutis Biotherapeutics, Inc.
-
Annual Revenue
$196.54 M229.74as on Dec 31, 2024
-
Net Profit
$-140.04 M46.58as on Dec 31, 2024
-
EBITDA
$-125.8 M47.41as on Dec 31, 2024
-
Total Equity Funding
$94.5 M (USD)
in 1 rounds
-
Latest Funding Round
$94.5 M (USD), Series C
Oct 17, 2019
-
Investors
Goldman Sachs
& 5 more
-
Employee Count
342
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Arcutis
Arcutis is a publicly listed company on the NASDAQ with ticker symbol ARQT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Arcutis
Arcutis offers a comprehensive portfolio of products and services, including ZORYVE cream, ZORYVE foam, ARQ-252, ARQ-255, and ARQ-234. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats plaque psoriasis and other skin conditions through targeted inhibition.
Addresses seborrheic dermatitis and scalp issues with anti-inflammatory effects.
Develops potential treatments for dermatologic indications via PDE4 inhibition.
Targets additional skin diseases in the company's immuno-dermatology pipeline.
Focuses on novel therapies for chronic inflammatory skin disorders.
Unlock access to complete
Unlock access to complete
Sales and Marketing
64 people
Leadership Team
49 people
Software Development Team
14 people
Finance and Accounting
9 people
Senior Team
8 people
Operations Team
7 people
Advisor Team
5 people
Legal and Compliance
5 people
Unlock access to complete
Funding Insights of Arcutis
Arcutis has successfully raised a total of $94.5M through 1 strategic funding round. The most recent funding activity was a Series C round of $94.5 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series C — $94.5M
-
First Round
First Round
(17 Oct 2019)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2019 | Amount | Series C - Arcutis | Valuation | HBM Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Arcutis
Arcutis has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Goldman Sachs, BlackRock and Vivo Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity firm
|
Founded Year | Domain | Location | |
|
Investment banking services are delivered across multiple financial sectors.
|
Founded Year | Domain | Location | |
|
Late-stage life sciences investments are managed via VC and PE.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Arcutis
Arcutis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Ducentis BioTheapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Preclinical therapeutics for inflammatory and auto-immune diseases are developed.
|
2015 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Arcutis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Arcutis Comparisons
Competitors of Arcutis
Arcutis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as LEO Pharma, Incyte, Formation Bio, DermBiont and Evommune, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drugs for treating dermatology diseases
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
AI-powered drug discovery platform for various diseases
|
|
| domain | founded_year | HQ Location |
Microbial therapeutics for skin diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic options for chronic inflammatory disorders
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Arcutis
Frequently Asked Questions about Arcutis
When was Arcutis founded?
Arcutis was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Where is Arcutis located?
Arcutis is headquartered in Westlake Village, United States. It is registered at Westlake Village, California, United States.
Who is the current CEO of Arcutis?
Frank Watanabe is the current CEO of Arcutis.
Is Arcutis a funded company?
Arcutis is a funded company, having raised a total of $94.5M across 1 funding round to date. The company's 1st funding round was a Series C of $94.5M, raised on Oct 17, 2019.
How many employees does Arcutis have?
As of Dec 31, 2024, the latest employee count at Arcutis is 342.
What is the annual revenue of Arcutis?
Annual revenue of Arcutis is $196.54M as on Dec 31, 2024.
What does Arcutis do?
Arcutis was founded in 2016 and is headquartered in Westlake Village, United States. Focus is placed on the development of immunotherapeutics targeting dermatology. Key products include topical roflumilast formulations for plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis, along with ARQ-252 cream as a JAK1 inhibitor for hand eczema and vitiligo, and ARQ-255 for alopecia areata. Operations center on advancing these topical treatments within the biopharmaceutical sector.
Who are the top competitors of Arcutis?
Arcutis's top competitors include LEO Pharma, Formation Bio and Incyte.
What products or services does Arcutis offer?
Arcutis offers ZORYVE cream, ZORYVE foam, ARQ-252, ARQ-255, and ARQ-234.
Is Arcutis publicly traded?
Yes, Arcutis is publicly traded on NASDAQ under the ticker symbol ARQT.
How many acquisitions has Arcutis made?
Arcutis has made 1 acquisition, including Ducentis BioTheapeutics.
Who are Arcutis's investors?
Arcutis has 6 investors. Key investors include Goldman Sachs, BlackRock, Vivo Capital, HBM Partners, and Omega Funds.
What is Arcutis's ticker symbol?
The ticker symbol of Arcutis is ARQT on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.